TrialInternational journal of hematology2026

Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial.

Tomoaki Fujisaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.